A5011910628- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Influenza Virus Research Studies
- Sepsis Diagnosis and Treatment
- Neuroscience of respiration and sleep
- Asthma and respiratory diseases
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Allergic Rhinitis and Sensitization
- Pneumonia and Respiratory Infections
- Cardiovascular Syncope and Autonomic Disorders
- Neurogenetic and Muscular Disorders Research
- Hemodynamic Monitoring and Therapy
- Human Health and Disease
- Emergency and Acute Care Studies
- Cardiovascular Health and Disease Prevention
- Muscle metabolism and nutrition
- Kawasaki Disease and Coronary Complications
- Non-Invasive Vital Sign Monitoring
- Muscle Physiology and Disorders
- Streptococcal Infections and Treatments
- Virology and Viral Diseases
- Cardiac Arrest and Resuscitation
- Pericarditis and Cardiac Tamponade
- Rabies epidemiology and control
Carol Davila University of Medicine and Pharmacy
2022-2024
Spitalului Clinic de Urgență pentru Copii Maria Sklodowska Curie
2021
In children, coronavirus disease 2019 (COVID-19) starts as a minor illness compared to adults, but during the ongoing COVID-19 pandemic, distinct SARS-CoV-2 variants and subvariants have changed options for therapies in both adults especially those with comorbidities such allergies. On 25 April 2022, Remdesivir (RDV), viral RNA-dependent RNA polymerase inhibitor, was approved by Food Drug Administration (FDA) treatment of pediatric patients 28 days older, weighing ≥3 kg, hospitalized or...
Abstract Background Internationally, there is an increasing trend in using Rapid Response Systems (RRS) to stabilize in‐patient deterioration. Despite a growing evidence base, remains limited understanding of the processes place aid early recognition and response deteriorating children hospitals across Europe. Aim/s To describe for deterioration European hospitals. Study Design A cross‐sectional opportunistic multi‐centre study, with paediatric in‐patients, descriptive self‐reported,...
The 2022–2023 influenza season in Romania was characterized by high pediatric hospitalization rates, predominated due to A subtypes (H1N1) pdm09 and H3N2. lowered population immunity after the SARS-CoV-2 pandemic subsequent stoppage of circulation, particularly children who had limited pre-pandemic exposures, influenced among immunosuppressed patients with concurrent medical conditions are at an increased risk for developing severe forms influenza. This study focused on characteristics...
Background: Given the potential for additional development to clarify a better knowledge of generally influence COVID-19 upon pediatric population, clinical symptoms SARS-CoV-2 infection in children and adolescents are still being explored. Morbidity is characterized by variable course. Our study’s goal was compare aspects 230 patients who analyzed positive were hospitalized between April 2020 March 2022. Methods: This retrospective study aimed characteristics coronavirus disease 2019,...
Background: Given the potential for additional development to clarify a better knowledge of overall impact COVID-19 on pediatric population, clinical symptoms SARS-CoV-2 infection in children and adolescents are still being explored. Morbidity is characterized by variable course. Our study's goal was compare aspects 230 patients who tested positive were hospitalized between April 2020 March 2022. Methods: In retrospective analysis, we compared two groups infectious diseases ward IX at...
Antiviral therapy such as Oseltamivir has been recommended for hospitalized children with suspected and confirmed influenza almost 20 years. The is officially authorized newborns two weeks of age or older, however, questions about its safety effectiveness still surround it. Our goal was to assess the epidemiological features consecutive seasonal in-fluenza cases in following COVID-19 pandemic also observe clinical ef-fectiveness tolerability oseltamivir who were not vaccinated against had...
Antiviral therapy such as oseltamivir has been recommended for hospitalized children with suspected and confirmed influenza almost 20 years. The is officially authorized newborns two weeks of age or older, however, questions about its safety effectiveness still surround it. Our goals were to assess the epidemiological features consecutive seasonal cases in following COVID-19 pandemic; observe clinical tolerability who not vaccinated against had different subtypes, including A(H1N1), A(H3N2),...
One of the main markers arterial stiffness is pulse wave velocity (PWV). This parameter well studied as a marker for end-organ damage in adult population, being considered strong predictor major cardiovascular events. study assessed PWV children with chronic kidney disease (CKD) risk. We conducted prospective observational single-center cohort 42 consecutively pediatric patients (9-18 years old) terminal CKD and dialysis, at Hemodialysis Department "M. S. Curie" Hospital, Bucharest. measured...
The outbreak of COVID-19 can be associated with cardiac and pulmonary involvement is emerging as one the most significant life-threatening complications in patients kidney failure receiving hemodialysis. Here, we report a critically ill case 13-year-old female patient acute pericarditis bilateral pleurisy, screened positive for SARS-CoV-2 RT-PCR, presented high fever, frequent dry cough, dyspnea tachypnea. COVID-19-induced myopericarditis has been noted to complication concomitant...
The 2022-2023 influenza season in Romania was characterized by high pediatric hospitalization rates, predominated A subtypes H1N1 and H3N2. Lowered population immunity to after the SARS-CoV-2 pandemic subsequent stoppage of circulation, particularly children who had limited pre-pandemic exposures, influenced among immunosuppressed, patients with concurrent medical conditions are at increased risk for developing severe forms influenza. This study focused on characteristics issues paediatric...
Asthma is the most common chronic disease affecting children, with a negative impact on their quality of life. often associated comorbid allergic diseases, and its severity may be modulated by immunoglobulin E (IgE)-mediated allergen sensitization. Omalizumab humanized monoclonal anti-IgE antibody, first biological therapy approved to treat patients aged ≥6 years severe asthma. The primary objective our study was investigate efficacy safety in Romanian children asthma.In this observational...
is one of the associated bacteria that can cause rare but high mortality hematological pathology known as purpura fulminans (PF) in both adults and children. Pediatric patients with PF progress quickly to sepsis multiorgan failure, especially immunocompromised individuals young Due thrombotic blockage blood arteries PF, there diffuse intravascular thrombosis hemorrhagic infarction skin, which evolves from ecchymosis skin necrosis, risk limb sequelae, fatality.
Collagen VI-related disorders constitute a spectrum of severities from the milder Bethlem myopathy (BM) to Ullrich congenital muscular dystrophy (UCMD), which is more severe, and an intermediate form characterized by muscle weakness that begins in infancy. Affected children are able walk, although walking becomes increasingly difficult starting early adulthood. They develop contractures ankles, elbows, knees, spine childhood. In some affected cases, respiratory muscles weakened, requiring...
Rabies is a life-threatening and vaccine-preventable infectious disease triggered by an RNA virus, part of the Rhabdoviridae family, Lyssavirus genus. It transmitted from infected saliva due to biting, but also contact with blood or organs rabid animals humans. Children are at high risk their inability defend themselves most deaths occur particularly incidence in this category (under age 15 years). Postexposure prophylaxis (PEP) standard life-saving if given early after exposure. We...
Background: Asthma is the most common chronic disease affecting children and altering their quality of life. The severity asthma often modulated by immunoglobulin E (IgE)-mediated allergen sensitization associated with comorbid allergic dis-eases. Omalizumab a humanized monoclonal antibody anti-IgE, first biological therapy approved to treat patients aged ≥6 years severe asthma. primary objective our study was investigate efficacy safety Omali-zumab in Romanian paediatric Methods: In...